The mechanism of muscarinic agonist-stimulated inositol phosphate formation in permeabilized ileal smooth muscle.
Muscarinic agonists and guanylyl-5'-imidodiphosphate (Gpp(NH)p) stimulated formation of inositol phosphates in permeabilized longitudinal smooth muscle of guinea pig ileum. Gpp(NH)p markedly potentiated the formation of inositol bisphosphate (IP2) and inositol trisphosphate (IP3) stimulated by carbachol, but increased inositol monophosphate formation (IP1) only slightly. Gpp(NH)p enhanced the formation of IP2 + IP3 induced by either acetylcholine or carbachol about fourfold in a synergistic manner, but enhanced the effects of oxotremorine and pilocarpine less than twofold in an additive manner. Elevation of Ca2+ concentration resulted in increases of the inositol phosphate levels stimulated by both carbachol and Gpp(NH)p. The optimal concentration of Ca2+ for carbachol-stimulated formations of IP2 + IP3 was shifted to a lower Ca2+ concentration in the presence of Gpp(NH)p. These findings suggest that muscarinic receptor-stimulated polyphosphoinositide hydrolysis in ileal smooth muscle results in inositol polyphosphate formation via GTP binding protein (G-protein). The muscarinic receptor-activated G-protein decreases the Ca2+ requirement of polyphosphoinositide hydrolysis. Muscarinic agonists stimulate inositol polyphosphate formation by interaction of the G-protein activation of a phosphoinositide specific phospholipase C with Ca2+ influx.
Honda
K
K
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Japan.
Takano
Y
Y
Kamiya
H
H
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D019204:GTP-Binding Proteins / Q000378:metabolism; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology*; D006168:Guinea Pigs; D006868:Hydrolysis; D007082:Ileum / Q000187:drug effects* / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology*; D009130:Muscle, Smooth / Q000187:drug effects* / Q000378:metabolism; D010095:Oxotremorine / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism*; D010862:Pilocarpine / Q000494:pharmacology; D013379:Substrate Specificity; D013997:Time Factors; D010738:Type C Phospholipases / Q000378:metabolism
D018721:Muscarinic Agonists; D010716:Phosphatidylinositols; D010862:Pilocarpine; D006165:Guanylyl Imidodiphosphate; D010095:Oxotremorine; D002217:Carbachol; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins; D000109:Acetylcholine; D002118:Calcium